Vivalis grows sales as demand for vaccine cell line increases
Vivalis nearly doubled revenues from its vaccine production platform in 2011 and has inked a third mAb discovery programme with Sanofi.
Revenue from Vivalis’ cell line, EB66, totalled €8.3m last year and accounted for more than four-fifths of total sales. The rest of the €10.3m ($13.4m) Vivalis earned in 2011 came from its VIVA|Screen antibody discovery technology.
Vivalis will use VIVA|Screen in its third monoclonal antibody (mAb) discovery collaboration with Sanofi Pasteur. In 2012 Vivalis will continue to invest in the platform and has allocated €8m for capital expenditures.
